Politan vs. Masimo: Quentin Koffey's Two-Year Proxy Campaign That Ended a 35-Year Founder
Sound United Misstep as the Catalyst · 2023 First Proxy Win · 2024 Second Proxy Sweep · Forced Removal of a 35-Year Founder-CEO · Healthcare and Audio Separation
Background
Joe Kiani founded Masimo in 1989 from his living room. He personally developed the Signal Extraction Technology pulse-oximetry algorithm, which measures blood-oxygen saturation accurately even in the presence of patient motion or low perfusion, and the technique quickly became the clinical standard. After the company's NASDAQ listing in 2007, Masimo grew into the de facto standard supplier for neonatal intensive-care units, operating rooms, and emergency departments. Kiani himself became one of the most recognizable founder-CEOs in medical devices. Masimo had no controlling shareholder, yet Kiani's grip on culture, strategy, and personnel decisions amounted to a form of founder control in practice.
On February 15, 2022, Masimo announced a $1.025 billion acquisition of Sound United, the parent of consumer audio brands Polk Audio, Denon, Marantz, and Bowers and Wilkins. The two businesses had almost nothing in common operationally. Kiani pitched a vision of audio and healthcare convergence anchored in home-based monitoring, but the market read it as a clear case of bad capital allocation. The shares fell 37 percent the next session, erasing roughly $5 billion of market value. A $1 billion purchase had destroyed five times that amount of shareholder equity in a single day.
Between August and September 2022, a new activist fund called Politan Capital Management disclosed an approximately 8.9 percent stake in Masimo via a Schedule 13D filing. Politan had been founded in 2021 by Quentin Koffey, a veteran of activist campaigns at D.E. Shaw and Senator Investment Group. Politan raised a dedicated pool of around $440 million specifically to fund the Masimo position, which became the largest single bet in the fund. Politan's core thesis was straightforward: reverse the Sound United misstep, install genuinely independent directors to check Kiani, and let the core medical-device franchise re-rate on its own merits.
Between April and June 2023, Politan launched its first proxy contest, nominating Koffey himself together with Michelle Brennan, a 30-year Johnson and Johnson veteran. Both leading proxy advisory firms, ISS and Glass Lewis, recommended in favor of Politan's nominees. At the June annual meeting, both Politan candidates were elected and two Kiani-aligned incumbents lost. For the first time, Masimo's board contained directors not selected by the founder. With only two of nine seats, Politan could not yet dictate decisions, but the foothold had been established.
Between April and September 2024, Politan ran its second proxy contest. This time it nominated Darlene Solomon, the former CTO of Agilent Technologies, and William Jellison, the former CFO of Stryker, emphasizing separation and financial expertise. Critically, Politan pushed for a direct vote against Kiani's own reelection to the board. At the September 19, 2024 annual meeting, Politan's nominees were elected once again and Kiani himself failed to retain his board seat. Masimo's COO Bilal Muhsin had threatened to resign if Kiani lost, but the bluff did not move the vote. Days later Kiani submitted his CEO resignation, and the board appointed Michelle Brennan as interim CEO. A 35-year founder era that began in a living room in 1989 ended with a single shareholder ballot.
Deal Summary
- Deal Value
- Politan position approximately $440M (~9 percent)
- Acquirer
- Politan Capital Management (Quentin Koffey)
- Target
- Masimo Corporation (MASI)
- Announced
- September 2022 (Politan 13D filing)
- Closed
- September 19, 2024 (Kiani fails to retain board seat, resigns as CEO days later)
- Country
- United States
Executive Summary
- Politan Capital (Quentin Koffey) accumulated a ~9 percent stake in 2022 and used two proxy contests over two years to oust Masimo founder-CEO Joe Kiani after 35 years
- Catalyst: Masimo's February 2022 announcement of the $1.025 billion Sound United acquisition, which sent the stock down 37 percent the next day and erased roughly $5 billion of market value, framing the campaign as a capital-allocation failure rather than a generic governance complaint
- First proxy contest (June 2023): Politan nominees Quentin Koffey and Michelle Brennan (formerly Johnson and Johnson) both elected to the nine-seat board; ISS and Glass Lewis both supported the activist slate
- Second proxy contest (September 2024): Politan nominees Darlene Solomon (formerly Agilent CTO) and William Jellison (formerly Stryker CFO) elected, and Kiani himself failed to be reelected; a founder voted off his own board
- Kiani's exit: He resigned as CEO on September 24, 2024, days after the meeting; Michelle Brennan was named interim CEO, ending a 35-year founder tenure through a proxy contest alone
- Strategic separation: In late 2024 Masimo formally moved to separate its core healthcare business from Sound United (consumer), delivering Politan's original thesis
- Structural significance: The first known case of a Fortune 1000 founder-CEO being removed through a proxy contest alone, without a takeover bid, exposing how thin founder control can be in widely held US public companies
Industry Overview
The pulse-oximetry market covers the real-time monitoring of blood-oxygen saturation in clinical settings, including neonatal ICUs, operating rooms, and emergency departments. The market is worth roughly $3 billion globally, and Masimo's Signal Extraction Technology has functioned as the clinical standard for more than two decades. Competitors include Medtronic (which absorbed Nellcor), Philips, and GE Healthcare, but Masimo has maintained an edge in motion artifact rejection and low-perfusion accuracy. Through the early 2020s, medical-device companies increasingly attempted to extend into home monitoring and wearables, but bridging clinical credibility and consumer price points remained difficult.
Global pulse-oximetry market
~$3B
Clinical plus home, 2024 estimate
Masimo clinical market share
~50%+
Effectively the standard in US neonatal ICUs
Sound United purchase price
$1.025B
Announced February 2022, non-core consumer audio
Market cap erased on announcement
~$5B
Stock down 37 percent the next session
Politan position size
~9 percent / ~$440M
Politan's largest single position
The capital-allocation playbook in medical devices typically involves core R and D, adjacent clinical extensions, and reinforcement of the regulated product pipeline. The Sound United deal hit none of those criteria. It pushed Masimo into a consumer category dominated by Apple and Sonos, where its clinical brand provided little competitive advantage. The fact that Politan's grievance was a specific, quantifiable capital-allocation failure rather than abstract governance complaint is what gave the campaign its force.
Key Players
Company Overview: Masimo Corporation (MASI)
Masimo is a medical-device company founded in 1989 by Joe Kiani in Irvine, California. Its core technology, Signal Extraction Technology, measures blood-oxygen saturation accurately under patient motion and low perfusion conditions, and has functioned as the clinical standard for monitoring in neonatal ICUs, operating rooms, and emergency departments. After its 2007 NASDAQ listing the business grew steadily, with revenue rising from roughly $0.86 billion in FY2018 to about $1.24 billion in FY2021. Following the April 2022 close of the Sound United acquisition, FY2022 revenue jumped to roughly $2.0 billion, but the company's identity, EBITDA margins, and capital-allocation discipline came under sustained scrutiny.
Founded
1989
Joe Kiani, Irvine, California
NASDAQ listing
August 2007
IPO price $17
FY2022 revenue (incl. Sound United)
~$2.0B
Healthcare ~$1.4B + Sound United ~$0.6B
FY2022 operating income
~$230M
Margins diluted post Sound United
Kiani founder stake
~5 percent
Widely held company, no controlling shareholder
Politan stake from 2022
~9 percent
Largest single outside shareholder
Control Battle Overview
Politan versus Masimo is the first known case in which an activist removed a sitting founder-CEO of a Fortune 1000 company through proxy contests alone, with no buyout offer involved. Quentin Koffey's fund secured four of nine board seats over two annual meetings and then used a direct vote against Kiani's own reelection to push him out of the company. The episode shows that founder control in widely held US public companies is far less robust than commonly assumed, and that the recommendations of ISS and Glass Lewis function as the decisive variable in modern activist campaigns.
The trigger was Masimo's February 15, 2022 announcement of the $1.025 billion Sound United acquisition. Investors viewed the move into consumer audio as a clear misallocation of capital, sending the shares down 37 percent the next session and erasing roughly $5 billion of market value. Six months later, Politan Capital surfaced with a ~9 percent stake and a clear thesis: reverse the Sound United decision and put genuinely independent directors on the board.
📈 Price Impact
The 37 percent drop the day after the Sound United announcement in February 2022 was effectively the direct trigger for Politan's entry. From there the first proxy win in June 2023, the second proxy win in September 2024, and the year-end separation decision drove a sustained recovery. Politan's position, entered around the mid-2022 low near ~$120 per share, was worth roughly $900M plus by late 2024, implying a mark-to-market gain of $400M plus.
🗡️ Battle Timeline
Announces $1.025B acquisition of Sound United, igniting the campaign
Masimo agrees to acquire Sound United, owner of Polk Audio, Denon, Marantz, and Bowers and Wilkins, for $1.025 billion. Kiani frames the deal as a convergence of audio and healthcare via home monitoring, but the market views it as a clear capital-allocation failure outside Masimo's medical-device core. The market reaction creates the direct opening for Politan.
Schedule 13D filed disclosing ~9 percent Masimo stake
New activist fund Politan Capital discloses an 8.9 percent position via Schedule 13D. Politan raised roughly $440 million of dedicated capital for the Masimo position, making it the fund's largest single bet. Koffey had previously led activist campaigns at D.E. Shaw and Senator Investment Group.
Public letter attacking Sound United and demanding board seats
Politan sends a public letter to the Masimo board arguing that the Sound United acquisition is value destructive and obscures the standalone worth of the healthcare franchise. The letter demands enhanced board independence, a strategic review committee, and a clear capital-allocation framework.
First proxy contest: Koffey and Brennan nominated
Politan nominates Quentin Koffey himself and Michelle Brennan, a 30-year Johnson and Johnson veteran, ahead of the 2023 annual meeting. Both ISS and Glass Lewis recommend in favor of Politan's slate. Masimo mounts a vigorous defense, but the advisor support proves decisive.
First proxy result: both Koffey and Brennan elected
At the June 26, 2023 annual meeting, both Politan nominees are elected, giving the activist fund two of nine board seats. Two Kiani-aligned incumbents are unseated. Masimo's board contains directors not selected by the founder for the first time.
Sound United divestiture pressure: strategic review begins
The two Politan-aligned directors push for separation or sale of Sound United inside the boardroom. In January 2024 Kiani himself proposes a separation of the consumer business, and the board agrees to study it. Politan's original thesis is now formally on the agenda.
Second proxy contest opens, Solomon and Jellison nominated, vote called against Kiani's reelection
Politan nominates Darlene Solomon, the former CTO of Agilent, and William Jellison, the former CFO of Stryker. Critically, Politan calls for a direct vote against Kiani's own reelection to the board. Masimo offers a settlement involving Jellison joining alone if Politan drops the campaign; Politan refuses.
Second proxy result: Solomon and Jellison elected, Kiani himself loses
At the September 19, 2024 annual meeting, both Politan nominees are elected and Kiani himself fails to be reelected to the board. ISS and Glass Lewis both recommended for Politan again. Masimo COO Bilal Muhsin had threatened to resign if Kiani lost, but the bluff fails to swing the vote.
Resigns as CEO, ending a 35-year founder tenure
Days after losing his board seat, Kiani submits his CEO resignation. He publicly characterizes Politan as Wall Street activists who damage medical innovation. The board appoints Michelle Brennan, who had joined as a Politan nominee in 2023, as interim CEO. A founder tenure that began in a living room in 1989 ends with a single proxy vote.
Formal separation of Healthcare and Sound United approved
Under the reconstituted board, Masimo formally moves to separate its core healthcare business from Sound United. Politan's 2022 thesis is essentially fully realized. The compensation and governance committees are now majority Politan-aligned, which materially changes how the company is run.
Announces $1.025B acquisition of Sound United, igniting the campaign
Masimo agrees to acquire Sound United, owner of Polk Audio, Denon, Marantz, and Bowers and Wilkins, for $1.025 billion. Kiani frames the deal as a convergence of audio and healthcare via home monitoring, but the market views it as a clear capital-allocation failure outside Masimo's medical-device core. The market reaction creates the direct opening for Politan.
Schedule 13D filed disclosing ~9 percent Masimo stake
New activist fund Politan Capital discloses an 8.9 percent position via Schedule 13D. Politan raised roughly $440 million of dedicated capital for the Masimo position, making it the fund's largest single bet. Koffey had previously led activist campaigns at D.E. Shaw and Senator Investment Group.
Public letter attacking Sound United and demanding board seats
Politan sends a public letter to the Masimo board arguing that the Sound United acquisition is value destructive and obscures the standalone worth of the healthcare franchise. The letter demands enhanced board independence, a strategic review committee, and a clear capital-allocation framework.
First proxy contest: Koffey and Brennan nominated
Politan nominates Quentin Koffey himself and Michelle Brennan, a 30-year Johnson and Johnson veteran, ahead of the 2023 annual meeting. Both ISS and Glass Lewis recommend in favor of Politan's slate. Masimo mounts a vigorous defense, but the advisor support proves decisive.
First proxy result: both Koffey and Brennan elected
At the June 26, 2023 annual meeting, both Politan nominees are elected, giving the activist fund two of nine board seats. Two Kiani-aligned incumbents are unseated. Masimo's board contains directors not selected by the founder for the first time.
Sound United divestiture pressure: strategic review begins
The two Politan-aligned directors push for separation or sale of Sound United inside the boardroom. In January 2024 Kiani himself proposes a separation of the consumer business, and the board agrees to study it. Politan's original thesis is now formally on the agenda.
Second proxy contest opens, Solomon and Jellison nominated, vote called against Kiani's reelection
Politan nominates Darlene Solomon, the former CTO of Agilent, and William Jellison, the former CFO of Stryker. Critically, Politan calls for a direct vote against Kiani's own reelection to the board. Masimo offers a settlement involving Jellison joining alone if Politan drops the campaign; Politan refuses.
Second proxy result: Solomon and Jellison elected, Kiani himself loses
At the September 19, 2024 annual meeting, both Politan nominees are elected and Kiani himself fails to be reelected to the board. ISS and Glass Lewis both recommended for Politan again. Masimo COO Bilal Muhsin had threatened to resign if Kiani lost, but the bluff fails to swing the vote.
Resigns as CEO, ending a 35-year founder tenure
Days after losing his board seat, Kiani submits his CEO resignation. He publicly characterizes Politan as Wall Street activists who damage medical innovation. The board appoints Michelle Brennan, who had joined as a Politan nominee in 2023, as interim CEO. A founder tenure that began in a living room in 1989 ends with a single proxy vote.
Formal separation of Healthcare and Sound United approved
Under the reconstituted board, Masimo formally moves to separate its core healthcare business from Sound United. Politan's 2022 thesis is essentially fully realized. The compensation and governance committees are now majority Politan-aligned, which materially changes how the company is run.
🔩 Key Instruments
⚔️ Offense Playbook— Politan Capital (Quentin Koffey)
Politan grounded its campaign in a specific, quantifiable capital-allocation failure (Sound United) rather than abstract governance grievances. The 37 percent drop on the deal announcement gave ISS and Glass Lewis the concrete evidence they needed to back the activist slate.
Election of Koffey and Brennan at the June 2023 annual meeting gave Politan two of nine board seats and access to the information flow inside the boardroom. The standard activist phase-one playbook executed cleanly.
Internal board pressure to separate or sell Sound United combined with external shareholder materials. The pincer eventually drove Kiani himself to propose a separation in January 2024.
Politan paired the nomination of Solomon and Jellison with a direct vote against Kiani's own reelection. This is the most aggressive move available to an activist short of a buyout. Sustained ISS and Glass Lewis support across two annual meetings was the deciding factor.
With four of nine board seats, Politan-aligned directors achieved working majorities on the compensation and governance committees. That gave the activists effective control over CEO contracts, executive compensation, and board procedures.
Rather than fire Kiani by vote, the structure was board loss leads to natural resignation. This produced a clean exit with limited litigation or severance friction and shifted a 35-year founder out of the company through a procedural route.
Immediately after Kiani's resignation, the board formally moved on the separation of Healthcare and Sound United, executing Politan's original thesis. The campaign closed with means and ends fully aligned.
🛡️ Defense Playbook— Joe Kiani and the founder-aligned Masimo board
Turning Point
2024-09-19Second proxy contest: Kiani himself fails to retain his board seat
At the September 19, 2024 annual meeting, Politan nominees Darlene Solomon and William Jellison were elected, and founder Joe Kiani himself was voted off the board. Two consecutive years of ISS and Glass Lewis support for the Politan slate proved decisive. The market priced the end of the founder era immediately, with the stock moving higher on the news. Days later Kiani resigned as CEO and Michelle Brennan was named interim CEO, completing the first known instance of a Fortune 1000 founder-CEO removed by proxy alone.
Final Verdict
Attacker WinsPolitan Capital (Quentin Koffey), decisive win
Margin: Two proxy contests over two years both won, four of nine board seats secured, founder-CEO resigned, Sound United separation forced
A decisive activist win on both short and long horizons. The first proxy in 2023 secured the foothold; the second in 2024 delivered the founder removal and the strategic separation that defined the original thesis. The defenders' tools, including the COO resignation threat and a late voluntary separation review, failed to swing the vote.
Deal Structure
There is no traditional purchase here. The structure is activist: open-market accumulation, two proxy contests, and a reconstituted board. Politan raised roughly $440 million of dedicated capital between May and August 2022 to acquire about 8.9 percent of Masimo in the open market, then converted that stake into four of nine board seats across two annual meetings before pushing for a direct vote against the founder's reelection.
Pre-Deal
Joe Kiani (founder-CEO)
Founded 1989, ~5 percent stake, dominant cultural and strategic control
Masimo Corporation (MASI)
NASDAQ-listed, no controlling shareholder
Legacy board (9 seats)
Kiani-aligned majority, de facto founder control
Other public shareholders
~95 percent (no controlling holder)
Post-Deal
Politan Capital
Quentin Koffey, ~9 percent stake, four board seats
Masimo Corporation (MASI)
Healthcare and Sound United separation underway
Reconstituted board (9 seats)
Four Politan-aligned, five independents, compensation and governance majorities now Politan-aligned
Michelle Brennan
Former Johnson and Johnson, interim CEO from September 2024
Joe Kiani
Resigned as CEO September 2024, voted off board, now outside the company
Other public shareholders
~91 percent dispersed ownership
Key Terms
Advisors
Both sides retained top-tier activism advisory benches. Politan worked with Sidley Austin on the proxy mechanics and Innisfree on solicitation. Masimo defended with Sullivan and Cromwell on the legal side and Goldman Sachs and Centerview on financial advice, including the consumer-business separation review. Two years of back-to-back proxy fights, with multiple rounds of settlement talks in between, likely translated into eight-figure advisory bills on each side.
Politan Capital (activist side) Advisors
Sidley Austin LLP
Legal advisor (activism and proxy mechanics)Advised Politan on proxy solicitation, SEC disclosure, and director nomination process
Wachtell, Lipton, Rosen and Katz (reported)
Legal advisor (governance and settlement)Press-reported role in settlement discussions; not confirmed
Innisfree M&A Incorporated
Proxy solicitorInstitutional vote solicitation and tabulation support
Masimo Corporation (defense side) Advisors
Sullivan and Cromwell LLP
Legal advisor (defense and proxy contest)Advised Masimo's board on activism defense and SEC disclosures
Goldman Sachs and Co.
Financial advisorDefense strategy, Sound United separation review, valuation analysis
Centerview Partners
Financial advisor (strategic review)Strategic alternatives review including potential whole-company sale and separation, 2023 to 2024
MacKenzie Partners (reported)
Proxy solicitorSolicitation and tabulation on the Masimo side
Advisor identifications are based on SEC filings and press reporting; actual scope may differ.
Financials
Units: $M (USD millions). Source: Masimo Corporation Annual Report (10-K) FY2018 through FY2022. FY2022 reflects approximately 8.5 months of Sound United contribution following the April 11, 2022 close.
| Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | USD 858M | USD 940M | USD 1,142M | USD 1,239M | USD 2,036M |
| COGS | USD 312M | USD 340M | USD 415M | USD 458M | USD 985M |
| Gross Profit | USD 546M | USD 600M | USD 727M | USD 781M | USD 1,051M |
| SG&A | USD 285M | USD 300M | USD 360M | USD 395M | USD 690M |
| Operating Income | USD 178M | USD 210M | USD 270M | USD 298M | USD 232M |
| EBITDA | USD 220M | USD 256M | USD 325M | USD 360M | USD 348M |
| EBITDA Margin | 25.6% | 27.2% | 28.5% | 29.1% | 17.1% |
Valuation
Politan argued that Masimo's core healthcare franchise was trapped in a conglomerate discount created by the Sound United deal. At Politan's entry around mid-2022, Masimo's market capitalization was roughly $6 billion. After the first proxy win in June 2023, the second proxy win in September 2024, and the Sound United separation decision in late 2024, the market capitalization recovered toward $10 billion. Politan's roughly 9 percent stake, entered at about $440 million, was worth roughly $900 million plus on a mark-to-market basis by late 2024, implying a mark-to-market gain of more than $400 million.
| Metric | Value | Notes |
|---|---|---|
| Masimo market cap (end of 2021) | ~$15B+ | Pre-Sound United, stock around $260 |
| Market cap after Sound United announcement (Feb 16, 2022) | ~$9 to 10B | Stock down 37 percent, roughly $5B erased in one day |
| Market cap at Politan entry (mid-2022) | ~$6B | Stock near low of ~$115, just before 13D filing |
| Politan entry stake value (mid-2022) | ~$440M | Roughly 9 percent, dedicated Politan vehicle |
| Market cap after first proxy (June 2023) | ~$7 to 8B | Stock recovering toward ~$140 |
| Market cap after Kiani exit (late 2024) | ~$10B | Stock at ~$180 plus, roughly $4B of recovery |
| Politan mark-to-market (late 2024) | ~$900M plus | Roughly $400M plus of mark-to-market gain, more than 2x entry |
| Masimo EV to EBITDA (2024 estimate) | ~25 to 30x | Healthcare standalone could trade at the higher end post separation |
Valuation figures are estimates based on public market data and SEC filings; Politan's actual entry and exit prices are not disclosed.
Share this deal
Deal Rationale
Why Politan targeted Masimo
- Sound United provided a clear, quantifiable capital-allocation failure. The 37 percent same-day drop gave the campaign a concrete piece of evidence, not just a generic governance narrative
- Widely held ownership structure with Kiani at roughly 5 percent and dispersed remaining shareholders meant that securing ISS and Glass Lewis recommendations was effectively sufficient to win a vote
- Sound United misstep made advisor support highly likely, and advisor support is the decisive variable in modern activist campaigns
- Masimo's core healthcare franchise was high quality. The standalone medical-device business could re-rate quickly once the consumer business was separated, making the means consistent with the ends
- As Politan's debut large-cap campaign after Koffey spun out of D.E. Shaw and Senator, success would establish the fund's brand and pricing power for years
Why Kiani and the Masimo board lost
- The Sound United deal was effectively impossible to defend. The 37 percent same-day drop served as a market verdict that no synergy narrative could reverse
- No controlling shareholder meant Kiani's roughly 5 percent stake could not outweigh ISS and Glass Lewis recommendations once they aligned with the activist
- ISS and Glass Lewis both backed Politan in 2023 and again in 2024, removing the most important defensive lever available to incumbents in modern proxy contests
- Kiani's January 2024 voluntary separation proposal arrived too late and read as a concession to Politan, undermining its defensive value
- The COO resignation threat was framed by Politan and proxy advisors as evidence of an entrenched founder-aligned culture, which intensified rather than blunted activist support
Post-Deal Assessment (As of June 2026 as of)
Following Kiani's September 2024 resignation, Masimo operated under interim CEO Michelle Brennan while preparing the separation of Healthcare and Sound United. Through 2025 the board moved toward a permanent CEO appointment and finalized the separation transaction. The stock continued to recover from late-2024 levels, with the healthcare franchise on a standalone basis trading near pre-Sound United multiples again. Politan retained its position as one of Masimo's largest shareholders and continued to exercise influence over the reconstituted board. Kiani publicly maintained his framing of Politan as Wall Street activists who damage medical innovation, but the market read the outcome as a clear activist win.
Positives
- All of Politan's core objectives delivered: Kiani removal, Sound United separation, four board seats, working majorities on key committees
- Stock recovery from ~$115 (2022 low) to ~$180 plus by late 2024, implying Politan mark-to-market gain of roughly $400M plus
- Confirmed once more that ISS and Glass Lewis recommendations are the decisive variable in modern activist campaigns
- Separation of Sound United allows the healthcare franchise to re-rate on its own merits, plausibly toward 30x EBITDA on a standalone basis
- First Fortune 1000 founder-CEO removed through a proxy contest alone, establishing a reference case for the limits of founder control in widely held US public companies
Risks & Concerns
- Successor CEO continuity, as the interim Brennan tenure may not extend, and the search for a permanent CEO could create transition noise
- Some merit to Kiani's argument that activist pressure can slow medical-device R and D and clinical trial pacing in the short term
- Execution and pricing risk on the Sound United separation, with weak consumer audio markets pressuring transaction value relative to the original $1.025B purchase price
- Likely acceleration of founder-protective measures (poison pills, classified boards, dual-class structures) at other US public companies in response to this case
- Politan's eventual exit timing and the market impact of unwinding a high-concentration position
This announcement appears as a matter of record only
Politan Capital Management
Acquirer
Masimo Corporation
Target
Politan x Masimo: Founder-CEO Joe Kiani Forced Out After 35 Years
Transaction Size
Politan stake ~$440M (~9 percent)
~$440M
EV / EBITDA
N/A (activist campaign)
Multiple
Closed
September 2024 (Kiani resigns as CEO)
Deal Date
Editor's Note
Politan versus Masimo is likely to be remembered as the first case in which an activist removed a sitting founder-CEO of a Fortune 1000 company through proxy contests alone, without a takeover bid. Two messages stand out. First, founder control in widely held US public companies is far thinner than commonly assumed. With no controlling shareholder and aligned proxy advisor recommendations, a 35-year founder can be removed by a single ballot. Second, the framing of an activist campaign matters as much as its substance. Politan's grievance was not abstract governance complaint but a specific, quantifiable capital-allocation failure, and the 37 percent same-day drop on the Sound United announcement was the concrete evidence that secured ISS and Glass Lewis support across two annual meetings. Compared to Elliott versus Twitter in 2020, where Jack Dorsey resigned voluntarily 18 months after the campaign, Politan pushed Kiani out by direct vote, marking a meaningful escalation in the offensive intensity of public-company activism.
Key Concepts in This Deal
Removal of a sitting founder-CEO through proxy contests alone, without a takeover bid. Politan vs. Masimo is the first known case of this pattern at the Fortune 1000 level.
A two-stage activist playbook. The first proxy gets the activist into the boardroom and resolves information asymmetry; the second proxy targets the founder directly. Now an emerging template in US activism.
Use of a non-core acquisition as the specific, quantifiable grievance grounding an activist campaign. The Sound United deal and its 37 percent same-day drop gave Politan the concrete evidence to secure ISS and Glass Lewis support.
Building from minority board representation to control of the compensation and governance committees, which then drives CEO contracts and board procedures. The four-of-nine seat structure proved sufficient.
Counter-narrative used by an ousted founder, framing the activist as Wall Street short-termism that damages mission-driven innovation. Kiani used this framing, but it failed to alter the vote.
Boardroom and external pincer pressure for separation or sale of a misaligned business. The combination eventually moved Kiani himself to propose a separation review in January 2024.
The observation that in widely held US public companies without dual-class shares or classified boards, founder control rests heavily on ISS and Glass Lewis. When those advisors back an activist, even a 35-year founder can be voted off.
The broader question of whether activist funds without sector operating experience have the legitimacy to drive operational decisions in regulated, R-and-D-heavy industries such as medical devices. Politan vs. Masimo has become a reference case in this debate.
Frequently Asked Questions
Who is Quentin Koffey and what is Politan Capital?
Politan Capital Management is an activist hedge fund founded by Quentin Koffey in 2021. Koffey previously led activist campaigns at D.E. Shaw and Senator Investment Group. Politan pursues a concentrated activism model, and the Masimo position was the fund's debut large-cap campaign and its largest single bet. Politan raised roughly $440 million of dedicated capital specifically for the Masimo investment.
Why was Masimo's Sound United acquisition so controversial?
Masimo's core business is medical-device pulse oximetry, while Sound United owned consumer audio brands including Polk Audio, Denon, Marantz, and Bowers and Wilkins. The two had little operational overlap. The $1.025 billion price tag was the largest in Masimo's history, and the consumer audio category is dominated by Apple and Sonos, where Masimo's clinical brand was not an advantage. The market's verdict was immediate: shares dropped 37 percent the next session, erasing roughly $5 billion of market value.
How exactly was Joe Kiani removed?
At the September 19, 2024 annual meeting, Politan's nominees Darlene Solomon and William Jellison were elected and Kiani himself failed to be reelected to the board. Days later he resigned as CEO, and the board appointed Michelle Brennan, who had joined as a Politan nominee in 2023, as interim CEO. Procedurally it was a director-loss followed by a voluntary CEO resignation, but in substance it was forced removal driven by the proxy contest.
Why did ISS and Glass Lewis back Politan?
Both proxy advisors recommended for Politan in 2023 and 2024 on the basis of the Sound United capital-allocation failure, Kiani's refusal to share information with the board, and concerns about board independence. The 37 percent same-day drop on the Sound United announcement was the most important piece of concrete evidence. The episode reinforced that quantifiable capital-allocation failures, not abstract governance critiques, are what move proxy advisors.
What does this mean for other founder-CEOs?
This is the first known instance of a Fortune 1000 founder-CEO being removed by proxy contest alone, without a buyout. It serves as a warning: in widely held US public companies without dual-class shares or classified boards, founder control rests on proxy advisor recommendations. When those go against the founder, even a 35-year incumbent cannot defend the seat. The case has accelerated discussion of founder-protective measures, including dual-class stock, classified boards, and poison pills, at other public companies.
How much did Politan make on the campaign?
Exact returns are not disclosed. Politan likely entered around mid-2022 at roughly $115 to $120 per share, and the stock was around $180 plus by late 2024, implying a roughly 50 percent mark-to-market gain. On a 9 percent stake entered for about $440 million, that maps to a position worth roughly $900 million plus and a mark-to-market gain of more than $400 million. Beyond the direct return, the campaign provided substantial brand value for what is now seen as a serious large-cap activist fund.
Was this helpful?
Share it with someone
Related Deals
Sources & Notes
- [1]Politan Capital Management, Schedule 13D, August 2022, SEC EDGAR
- [2]Masimo Corporation, Form 8-K, February 15, 2022 (Sound United acquisition announcement)
- [3]Masimo Corporation, Form 8-K, September 25, 2024 (Joe Kiani resignation as CEO)
- [4]Masimo Corporation, DEFA14A and DFAN14A filings related to the 2024 proxy contest, SEC EDGAR
- [5]MedTech Dive, Masimo CEO Kiani resigns following board battle defeat, September 2024
- [6]MedTech Dive, Masimo investor claims proxy war win as CEO Kiani fails to retain board seat, September 2024
- [7]MassDevice, Masimo stock falls as The Street ponders $1B Sound United acquisition, February 2022
- [8]MassDevice, Masimo looks to separate consumer business two years after $1 billion buyout, 2024
- [9]Strata-gee, Masimo Acquisition of Sound United Spurs Ugly Activist Shareholder Lawsuit
- [10]Joe Kiani, Wikipedia entry, Masimo founder profile and 2024 resignation
- [11]Masimo Corporation, Annual Report (10-K), FY2018 through FY2022